Silver Book Fact

The use of imatinib (Gleevec) has increased the eight-year survival rate for early chronic-phase myelogenous leukemia from 65% to 84%.

Romley J, Sanchez Y, Penrod J, Goldman D, et al. Survey Results Show that Adults are Willing to Pay Higher Insurance Premiums for Generous Coverage of Specialty Drugs. Health Affairs. 2012; 31(4): 683-690. https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2011.1301

Reference

Title
Survey Results Show that Adults are Willing to Pay Higher Insurance Premiums for Generous Coverage of Specialty Drugs
Publication
Health Affairs
Publisher
Project HOPE
Publication Date
2012
Authors
Romley J, Sanchez Y, Penrod J, Goldman D, et al.
Volume & Issue
Volume 31, Issue 4
Pages
683-690
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • A modest decrease of 1% in cancer mortality has been estimated to be worth $500 billion in social value.  
  • FDA approved cancer advances
     
  • According to the Pharmaceutical Research and Manufacturers of America, one of the most promising medicines in development is for glioblastoma. The medicine singles out and latches onto the receptors on…  
  • Without screening and adjuvant therapy, the death rate for breast cancer would have increased by about 30 percent between 1975 and 2000.  
  • Gains in healthy years of life and social value from cancer R&D